Tag: metastatic castration-sensitive prostate cancer

Androgen deprivation in prostate cancer: intermittent may compromise survival

Radiotherapy and abiraterone improve survival in low-volume metastatic castration-sensitive prostate cancer

byNeel Mistryand1 others

December 18, 2024

1. Progression-free survival improved significantly in patients with low-volume disease who received abiraterone and radiotherapy. 2. The addition of radiotherapy ...

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

byJessie Willisand1 others

May 11, 2022

1. A combination of androgen deprivation therapy, docetaxel, and abiraterone (“triplet therapy”) had the best overall survival and progression-free survival ...

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result